Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

BACKGROUND: Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: To evaluate long‐term efficacy and safety of apremilast in biologic‐naive patients with moderate to severe plaque psoriasis and safety of switching from...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Eur Acad Dermatol Venereol
Hlavní autoři: Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Original Articles and Short Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873268/
https://ncbi.nlm.nih.gov/pubmed/29220542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14738
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky